Project cooperation
Develop our Dual CAR-T cell (CD33+CLL1) against AML
BAT is developing BAT-33/CLL1, a dual-target CAR T cell therapy for patients with Acute Myeloid Leukaemia (AML). By targeting both CD33 and CLL1, our approach aims to improve disease control in patients who relapse after standard treatments.
- Consortium/Coordinator seeks Partners
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
CEO at Batazu Advanced Therapeutics
Lisbon, Portugal